ArticleAsian journal of andrology2026
The importance of the season of biopsy on the Gleason score on biopsy: does exposure to sunshine have an influence?
Article in Asian journal of andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Seasonal Gleason scores: compelling observations amid methodological complexity.Asian journal of andrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The circadian clock is strongly influenced by the sun exposure and prostate cancer has been shown to be inversely proportional to it. We investigated whether PCa aggressiveness in Montreal, Quebec, Canada, differs over the months during or following potentially longer exposure to sunlight. We analyzed 3447 patients treated between January 1995 and December 2023 with primary radiotherapy for localized PCa. We investigated whether the month when diagnostic biopsy was performed was associated with a more frequent diagnosis of a primary Gleason score (pGS) of 4 or 5. We grouped the months of biopsy into the four quarters (Q1-4) of the year. Multivariable logistic regression was used to predict a pGS of 4 or 5, adjusted for age and year of biopsy. There were significantly fewer biopsies ( P = 0.027) with pGS 4 or 5 in the last 3 months of the year (Q4; 19.0%) than those in Q1-3 (22.9%). Age, prostate-specific antigen (PSA) level, and the number of positive biopsies were not significantly different between Q4 versus Q1-3. In multivariate logistic regression analysis, a biopsy in Q4 was significantly predictive of a lower risk of pGS 4 or 5 (odds ratio [OR]: 0.77, 95% confidence interval [CI]: 0.63-0.93, P = 0.007), as was older age (P < 0.001), but not the year of biopsy ( P = 0.76). In conclusion, patients biopsied during Q4 had a 23% lower risk of a pGS 4 or 5 on diagnostic biopsy than those biopsied during the previous 9 months. Our results are not a proof of causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.